Dianthus initiated with an Overweight at Cantor Fitzgerald

Cantor Fitzgerald initiated coverage of Dianthus Therapeutics with an Overweight rating and no price target. Dianthus is developing DNTH103, a complement pathway inhibitor, for three neuro-autoimmune disease indications, the analyst tells investors in a research note. The firm models over $1.6B in unadjusted sales five years post launch, which it believes could drive significant upside to the company’s current market cap of $684M. Cantor expects the shares to appreciate from current levels as C1s inhibitors are increasingly de-risked in multiple indications.